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Abstract
Aims/hypothesis During the A/H1N1 2009 (A/California/04/
2009) pandemic, mass vaccination with a squalene-containing
vaccine, Pandemrix®, was performed in Sweden and Finland.
The vaccination was found to cause narcolepsy in children
and young adults with the HLA-DQ 6.2 haplotype. The aim
of this study was to investigate if exposure to Pandemrix®
similarly increased the risk of islet autoimmunity or type 1
diabetes.
Methods In The Environmental Determinants of Diabetes in
the Young (TEDDY) study, children are followed
prospectively for the development of islet autoimmunity and
type 1 diabetes. In October 2009, when the mass vaccination
began, 3401 children at risk for islet autoimmunity and type 1
diabetes were followed in Sweden and Finland. Vaccinations
were recorded and autoantibodies against insulin, GAD65 and
insulinoma-associated protein 2 were ascertained quarterly
before the age of 4 years and semi-annually thereafter.
Results By 5 August 2010, 2413 of the 3401 (71%) children
observed as at risk for an islet autoantibody or type 1 diabetes
on 1 October 2009 had been vaccinated with Pandemrix®. By
31 July 2016, 232 children had at least one islet autoantibody
before 10 years of age, 148 had multiple islet autoantibodies
and 96 had developed type 1 diabetes. The risk of islet
autoimmunity was not increased among vaccinated children.
The HR (95% CI) for the appearance of at least one islet
autoantibody was 0.75 (0.55, 1.03), at least two autoanti-
bodies was 0.85 (0.57, 1.26) and type 1 diabetes was 0.67
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(0.42, 1.07). In Finland, but not in Sweden, vaccinated
children had a lower risk of islet autoimmunity (0.47 [0.29,
0.75]), multiple autoantibodies (0.50 [0.28, 0.90]) and type 1
diabetes (0.38 [0.20, 0.72]) compared with those who did not
receive Pandemrix®. The analyses were adjusted for
confounding factors.
Conclusions/interpretation Children with an increased
genetic risk for type 1 diabetes who received the
Pandemrix® vaccine during the A/H1N1 2009 pandemic
had no increased risk of islet autoimmunity, multiple islet
autoantibodies or type 1 diabetes. In Finland, the vaccine
was associated with a reduced risk of islet autoimmunity and
type 1 diabetes.
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Introduction
Clinical diagnosis of type 1 diabetes is preceded by an
autoimmune destructive process against the pancreatic islet
beta cells; a prodromal period that may last a few months or
several years. The risk of developing autoimmunity in
genetically susceptible children is widely considered to be
increased by perinatal or early childhood environmental
exposures [1]. While genetic risk factors, such as HLA-DR-
DQ [2] and non-HLA genetic factors [3], have been
implicated, the environmental conditioning or trigger
exposures have not yet been defined. In The Environmental
Determinants of Diabetes in the Young (TEDDY) study, we
have the opportunity to analyse triggers in relation to
seroconversion to islet autoimmunity as a first primary
endpoint, as over 70% of children with multiple islet
autoantibodies develop type 1 diabetes over a 10-year period
[4]. It has been speculated that vaccinations early in life may
alter the immune response to infections, leading to a disturbed
capacity to distinguish between self and non-self and thereby
increasing the risk of autoimmune reactions. However,
previous studies do not support the notion that type 1 diabetes
can be triggered by vaccinations [5, 6].
During the H1N1 influenza pandemic in 2009–2010, mass
vaccination of both children and adults took place in many
countries. In Sweden and Finland, Pandemrix®, a vaccine
containing the squalene-based adjuvant ASO3, was used while
other countries used other types of vaccine. A few months after
the Pandemrix® vaccination programme, the incidence of new
narcolepsy diagnoses increased sharply in both countries.
Additional investigations seeking an understanding of the
potential mechanisms associated with Pandemrix® and
narcolepsy suggested that the Pandemrix® vaccination might
have resulted in the loss of orexin-producing neurons, leading
to the development of narcolepsy in these individuals [7–9].
Themechanism that mediates this effect is not fully understood,
but it seems that both the composite influenza virus vaccine and
the squalene adjuvant could contribute to the induction of
orexin-specific autoimmunity [10].
The aim of the present study was to investigate if exposure
to the Pandemrix® vaccine affected the incidence of islet
autoimmunity and type 1 diabetes in genetically susceptible
children. This was an observational study carried out among
high-risk children followed prospectively from birth [11].
Methods
Participants Participants were included in the TEDDY study,
a prospective cohort study funded by the National Institutes of
Health with the primary goal to identify environmental causes
of type 1 diabetes [11]. The association between the
Pandemrix® vaccination and the risk of narcolepsy was
initially found in Finland and later in Sweden, representing
two of the TEDDY countries. The other countries included in
TEDDY are the USA (with three centres in Colorado,
Georgia/Florida and Washington) and one additional centre
in Europe (Germany). Although the same protocol applied
to all TEDDY centres [11], the current analyses only include
children from Sweden and Finland as Pandemrix® was
exclusively, and with a high coverage, administered in those
TEDDY countries.
At all TEDDY sites, children (n = 440,000) representing
both the general population and first-degree relatives to
individuals with type 1 diabetes were screened at birth during
the period 1 September 2004 to 1 March 2010 for genetic type
1 diabetes risk, defined by HLA genotype, as described
previously [12, 13]. A high-risk population of 8676 children
was recruited for follow-up from 3 months of age. During the
first 4 years, all children were examined every third month.
Thereafter and currently, children still at risk for islet
autoimmunity are being followed biannually until the age of
15 years [11]. Children with one or several islet autoantibodies
continuemonitoring on a 3-month schedule after 4 years of age.
All participants and their legal representatives have given
informed consent to participate in the study. The regional ethics
committees in all participating countries approved the study.
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The mass vaccination period in both Sweden and Finland
was during the winter of 2009–2010 (1 October to 31 March).
On 1 October 2009, 727/4358 (17%) children were no longer
considered at risk for type 1 diabetes as they had either
developed the disease (n = 30) or dropped out of the study
(n = 697) and were therefore excluded from the analyses. An
additional 181 childrenwere excluded for leaving the TEDDY
study temporarily and re-joining after the mass vaccination, 13
were excluded for being HLA ineligible and 36 children were
excluded as they either failed to have study outcomes mea-
sured (n = 6) or vaccination data collected (n = 30) after the
mass vaccination. Of the remaining 3401 children still consid-
ered at risk of developing type 1 diabetes on 1 October 2009,
3256 had not yet developed islet autoimmunity and 3329 had
not developed multiple islet autoantibodies (Fig. 1).
Autoantibodies and type 1 diabetes The primary outcome in
the TEDDY study is the development of persistent confirmed
autoantibodies to glutamic acid decarboxylase (GADA),
insulinoma-associated protein 2 (IA-2A) or insulin (IAA),
measured at all study visits and analysed by radiobinding
assays [14, 15]. All samples were initially analysed at the
reference laboratory at the University of Bristol, UK. Islet
autoimmunity was defined as persistent (at least two
consecutive visits) presence of one or more of these autoanti-
bodies, confirmed in the second reference laboratory at the
Total enrolled in TEDDY
n=8676
Family from Sweden or
Finland
n=4358
Still enrolled Oct 2009
n=3631
HLA eligible for study and followed for
at least one outcome
n=3401
At risk for islet autoimmunity on 1
October 2009
n=3256
At risk for multiple islet autoantibodies
on 1 October 2009
n=3329
At risk for type 1 diabetes on 1 October
2009
n=3401
Family from US or Germany
(n=4318)
Developed islet autoantibodies
before October 2009
n=73
Developed multiple islet
autoantibodies before Oct
2009
n=60
Negative for islet
autoantibodies and no longer
being tested (n=12)
HLA ineligible (n=13) or not
followed for outcomes (n=6) or
for vaccination information
(n=30)
Left study and rejoined (n=181)
Out of study:
Diagnosed with type 1 diabetes
(n=30) or dropped out of study
(n=697)
In TEDDY continuously
n=3450
Fig. 1 Flow chart of the study population
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Barbara Davis Center for Childhood Diabetes (University of
Colorado, Denver, CO, USA) and multiple islet autoanti-
bodies was defined as more than one persistent confirmed
autoantibody. Type 1 diabetes was diagnosed using the
ADA criteria [16].
Vaccination data At all TEDDY clinic visits, the parents
were asked to report if the child had been given any
vaccination since the last visit. Type, dose and date of
vaccination was recorded by a TEDDY nurse. If possible,
the vaccination was verified by checking the child’s
vaccination card. The mass vaccination with Pandemrix®
began on 1 October 2009. Among the 3401 children
considered at risk for type 1 diabetes on this date, 2413 had
a recorded Pandemrix® vaccination by 5 August 2010. If
more than one dose was received, the date of first vaccination
was included in the analyses.
Statistical methods Children were followed for outcomes
from 1 October 2009. For children born between 1 October
2009 and 1March 2010 the follow-up was from birth. Only 26
children born after the mass vaccination had begun were
vaccinated for H1N1. Differences in cumulative incidence of
islet autoantibodies, multiple islet autoantibodies and type 1
diabetes between vaccination groups were examined in
Kaplan–Meier analyses. For children who were vaccinated,
survival time was from date of first vaccination. For children
who were not vaccinated for H1N1, survival time was from 1
October 2009. Time-dependent Cox proportional hazard
models were used to explore if vaccination for H1N1 modi-
fied the risk of type 1 diabetes outcomes. In the Cox models,
the observations were left truncated before 1 October 2009
and right censored after 31 July 2016 or after the age of
10 years. All models were adjusted for country of residence,
the presence of a first-degree relative with type 1 diabetes,
HLA, sex and age of child on 1 March 2010. Final models
were also adjusted for other genetic type 1 diabetes risk factors
(INS-23Hph1 [rs689], PTPN22 R620W [rs2476601], CTLA4
T17A [rs231775], and SNPs rs2292239 inERBB3, rs3184504
in SH2B3, rs10517086 and rs12708716 in CLEC16A,
rs4948088 in COBL), maternal education at 9 months of age
and probiotic use before 90 days of age. Maternal education
was categorised as primary education (n = 764), some college/
trade school (n = 719), college degree (n = 1851) or missing
education (n = 67). In a competing risk analysis, we explored
the relationship between Pandemrix® vaccination and the
cause-specific risk of IAA or GADA as the first solitary
appearing islet autoantibody [17]. In each model, children
who seroconverted for a competing islet autoantibody that
was not of interest were censored after the day of seroconver-
sion. The final models were also examined by age of child (< 2
and ≥ 2 years) as the incidence of IAA and GADA as the first
appearing islet autoantibody is known to differ considerably
before and after 2 years of age [17]. The association between
Pandemrix® vaccine (yes, no) and type 1 diabetes outcomes
were reported as HRs with 95% CIs. p values < 0.05 were
considered statistically significant. To examine for increased
risk of type 1 diabetes outcomes within subgroups,
interactions were tested between whether or not the child
had received the H1N1 vaccine and HLA, sex, country of
residence, age or family history of type 1 diabetes. The
interactions were considered descriptive and secondary and a
p value < 0.05 was considered an important interaction to
investigate further. Statistical analysis was performed using
SAS version 90.4 (SAS Institute, Cary, NC, USA).
Results
Of the 3401 children considered at risk for type 1 diabetes as
of 1 October 2009, 2413 (70.9%) were vaccinated with
Pandemrix®. Of the children vaccinated, 98.8%
(2385/2413) received their first vaccination between 1
October 2009 and 31 March 2010, five had their first
vaccination in September 2009 and 22 had their vaccination
between 1 April and 5 August 2010. Of the children
vaccinated in Sweden, 72.9% (1010/1385) received a second
Pandemrix® vaccination within a median 2.0 (interquartile
range 1.5–3.0) months; however, only 0.6% (6/1028) of
children from Finland received a second vaccination. The
vaccination coverage by country and age of the child on 1
March 2010 (all children born) is shown in Fig. 2. In both
Finland and Sweden, the coverage was low before the age of
6 months (all p < 0.001) and children were more likely to
receive the vaccine if the mother had a college degree when
the child was 9 months of age (see electronic supplementary
material Table 1).
Fig. 2 H1N1 coverage as of 1 March 2010 among children born in
Finland and Sweden; coverage shown for children aged < 6 months (solid
black bars), 6–11 months (solid white bars), 12–23 months (solid light
grey bars), 24–36 months (solid dark grey bars) and ≥ 36 months (light
grey striped bars)
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At the time of the current analyses (31 July 2016), 232
children had developed persistent confirmed islet autoanti-
bodies by 10 years of age (135 in Sweden and 97 in Finland),
148 children had developed multiple islet autoantibodies (81 in
Sweden and 67 in Finland) and 96 had developed type 1 dia-
betes (47 in Sweden and 49 in Finland) (Table 1).
There was no increased risk of any islet autoantibody (HR
0.76 [95% CI 0.57, 1.02]), multiple islet autoantibodies (HR
0.92 [95% CI 0.63, 1.35]) or type 1 diabetes (HR 0.68 [95%
CI 0.43, 1.06]) among the vaccinated children. In contrast, the
risk of any islet autoantibody (HR 0.50 [95% CI 0.32, 0.78]),
multiple islet autoantibodies (HR 0.56 [95% CI 0.33, 0.96])
and type 1 diabetes (HR 0.41 [95% CI 0.23, 0.76]) was
decreased among vaccinated children in Finland, but this
was not seen in Sweden (HR 1.01 [95% CI 0.68, 1.50], HR
1.41 [95% CI 0.82, 2.46] and HR 1.10 [95% CI 0.53, 2.24],
respectively) (Table 1). HLA genotype, age at vaccination, sex
or family history of type 1 diabetes did not modify the
association between H1N1 vaccination and outcomes
(Table 1).
The cumulative incidence of each of the outcomes in the
two countries after vaccination or while considered at risk
after 1 October 2009 is shown in Fig. 3. In Finland, the
decreased risk of islet autoimmunity and multiple islet auto-
antibodies for the vaccinated children was seen primarily
between 6 months and 36 months after the first vaccination.
The cause-specific risk of IAA as a first solitary autoantibody,
before other islet autoantibodies appear, primarily occurred in
younger children and tended to be more frequent in Finland
than in Sweden [17]. Therefore, we examined whether the
incidence of IAA or GADA as first appearing solitary auto-
antibody separately, or any islet autoantibody, in Finland and
Sweden, in both younger and older children shortly after
vaccination were influenced by the vaccination after adjusting
for previously reported risk factors. Genetic risk factors
previously found to be associated with islet autoimmunity,
Table 1 Proportional hazards models of HIN1 vaccination (yes vs no) on risk of islet autoantibodies, multiple islet autoantibodies and type 1 diabetes
before age 10 years adjusting for factors in table and also stratified by the factor subgroups
Factor and group Total (Na) H1N1 vaccination in relation to risk
of islet autoantibodies
H1N1 vaccination in relation to risk
of multiple islet autoantibodies
H1N1 vaccination in relation to risk
of type 1 diabetes
Events
(n)
HR
(95% CI)
p valueb Events
(n)
HR
(95% CI)
p valueb Events
(n)
HR
(95% CI)
p valueb
All children 3401 232 0.76 (0.57, 1.02) 148 0.92 (0.63, 1.35) 96 0.68 (0.43, 1.06)
Country
Finland 1438 97 0.50 (0.32, 0.78) 67 0.56 (0.33, 0.96) 49 0.41 (0.23, 0.76)
Sweden 1963 135 1.01 (0.68, 1.50) 0.008 81 1.41 (0.82, 2.46) 0.01 47 1.10 (0.53, 2.24) 0.02
Sex
Female 1659 103 0.91 (0.58, 1.43) 63 0.80 (0.45, 1.43) 46 0.60 (0.31, 1.16)
Male 1742 129 0.67 (0.46, 0.99) 0.46 85 1.03 (0.62, 1.72) 0.43 50 0.77 (0.41, 1.45) 0.35
Family history
General population 3123 199 0.69 (0.50, 0.94) 122 0.83 (0.55, 1.26) 78 0.64 (0.39, 1.06)
First-degree relative 278 33 1.30 (0.54, 3.13) 0.12 26 1.66 (0.59, 4.68) 0.15 18 0.71 (0.24, 2.07) 0.65
HLA-DR
DR-4/4 665 41 0.85 (0.41, 1.78) 27 1.40 (0.52, 3.74) 20 0.55 (0.20, 1.49)
DR-4/8 695 47 0.61 (0.32, 1.17) 25 0.62 (0.25, 1.56) 13 0.13 (0.04, 0.49)
DR-3/4 1298 111 0.72 (0.47, 1.10) 80 0.76 (0.46, 1.26) 53 0.74 (0.40, 1.38)
DR-3/3 649 28 0.77 (0.32, 1.87) 0.68 12 1.73 (0.41, 7.30) 0.32 7 7.74 (0.80, 74.7) 0.14
Age on 1 March 2010
< 1 year 752 71 0.76 (0.46, 1.25) 44 0.75 (0.40, 1.39) 26 0.26 (0.10, 0.70)
1 year 646 50 1.13 (0.55, 2.33) 33 1.52 (0.58, 4.01) 16 2.00 (0.45, 8.97)
2 year 649 43 0.75 (0.36, 1.58) 25 0.53 (0.20, 1.39) 23 0.70 (0.26, 1.91)
3 year 587 34 0.76 (0.34, 1.70) 23 1.07 (0.36, 3.17) 17 0.61 (0.21, 1.83)
≥ 4 years 722 34 0.57 (0.26, 1.24) 0.73 23 2.48 (0.57, 10.9) 0.07 14 1.24 (0.27, 5.71) 0.19
a Total number of children on 1 October 2009 who were observed at risk of type 1 diabetes; 145 were no longer observed at risk of islet autoimmunity,
and 72 no longer at risk of multiple islet autoantibodies
b p value test of multiplicative interaction between subgroups; all HRs are adjusted for factors in table
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including INS -23Hph1 (rs689), PTPN22 R620W
(rs2476601), CTLA4, T17A (rs231775), SNPs rs2292239
in ERBB3 , rs3184504 in SH2B3 , rs10517086 and
rs12708716 in CLEC16A, and rs4948088 in COBL [18]
were included in this analysis, as well as probiotic use
before 90 days of age [19], maternal age at birth of child
and maternal education (Table 2). After adjustment, the HR
for islet autoantibodies (0.47 [95% CI 0.29, 0.75]), for
multiple islet autoantibodies (0.50 [95% CI 0.28, 0.90])
and for type 1 diabetes (0.38 [95% CI 0.20, 0.72])
remained significantly decreased in Finland. Moreover,
cause-specific risk of IAA as the first appearing islet
autoantibody was decreased, particularly among children
vaccinated at younger than 2 years of age (Table 2).
In Sweden, 1.2% of children observed at risk for type 1
diabetes were vaccinated with the seasonal flu vaccine before
(0.2%) or only after (1.0%) the mass vaccination for H1N1
had begun. The frequency of receiving the seasonal flu
vaccine was similar between children who were vaccinated
for H1N1 (1.3%) compared with children who were not
(1.0%). In Finland, 58.7% of children who were vaccinated
for H1N1 had a seasonal flu vaccine either before (36.1%) or
only after (22.6%) the H1N1 vaccination. This was
significantly higher compared with the children who were
not vaccinated for H1N1 (28.3% received seasonal
flu vaccine,11.7% before [p < 0.001] and 16.6% only after
[p ≤ 0.01]). Mothers could also have received the seasonal
flu vaccine during pregnancy; however, the percentage was
Fig. 3 Kaplan–Meier curves
showing the cumulative
percentage of vaccinated (solid
line) and unvaccinated (dashed
line) children developing islet
autoantibodies (IA) in (a) Finland
with an average follow-up time of
5.3 years for vaccinated (n = 976)
and 4.7 years for unvaccinated
(n = 397) children and (b)
Sweden with an average follow-
up time of 5.4 years for
vaccinated (n = 1309) and
5.0 years for unvaccinated
(n = 563) children; multiple islet
autoantibodies in (c) Finland with
an average follow-up time of
5.3 years for vaccinated
(n = 1000) and 4.8 years for
unvaccinated (n = 400) children
and (d) Sweden with an average
follow-up time of 5.5 years for
vaccinated (n = 1347) and
5.2 years for unvaccinated
(n = 569) children. Type 1
diabetes (T1D) in (e) Finlandwith
an average follow-up time of
5.5 years for vaccinated
(n = 1027) and 5.1 years for
unvaccinated (n = 410) children
and (f) Sweden with an average
follow-up time of 5.7 years for
vaccinated (n = 1384) and
5.4 years for unvaccinated
(n = 578) children, after the child
was vaccinated or after 1 October
2009 for the children who were
not vaccinated
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similar between countries (Finland, 2.1%; Sweden 1.4%).
Interestingly, of the 1.7% (58/3381) of mothers who did get
the seasonal flu vaccine during pregnancy, 6.2% (46/743)
were mothers of younger children (aged < 1 year on 1
March 2010) and the vaccine was given towards the end of
the mass vaccination. Of these mothers, only 2/46 had their
child vaccinated for H1N1. Seasonal flu vaccine administered
to mothers during pregnancy or children during follow-up did
not explain the association between H1N1 vaccination and
type 1 diabetes outcomes. The seasonal flu vaccine did not
have a modifying effect on the association between H1N1
vaccination and type 1 diabetes outcomes (data not shown).
Furthermore, in Sweden, a second vaccination dose did not
influence any of the type 1 diabetes outcomes (data not
shown).
When analysing these results over time, we did not find any
short- or long-term initiating or accelerating effects of the
Pandemrix® vaccination on risk of islet autoimmunity,
multiple islet autoantibodies or type 1 diabetes.
Discussion
In this study, we investigated whether risk of islet
autoimmunity and type 1 diabetes is increased in children
who have been vaccinated with the squalene (ASO3)-
containing H1N1 flu vaccine (Pandemrix®). Notably,
Pandemrix® has been associated with autoimmunity to
orexin-producing cells and the development of narcolepsy.
As such, we hypothesised that this vaccine may not only
promote autoimmunity to orexin-producing cells but also islet
autoantigens. The results of our study do not support this
hypothesis and argue against any connection between the
H1N1 mass vaccination campaign and the risk of type 1
diabetes. In fact, we found that the incidence of type 1 diabetes
outcomes in Finland was actually lower in children vaccinated
against H1N1 than in non-vaccinated children. Theoretically,
this finding could indicate that the vaccine may have reduced
the risk of type 1 diabetes in higher risk populations by
unknown mechanisms.
In the prospective cohort of children followed in the
TEDDY study, we have the unique capacity to analyse
environmental factors associated with the initiation of islet
autoimmunity and development of type 1 diabetes. Type 1
diabetes is preceded by progressive autoimmune destruction
of beta cells, which can last just a few months or up to many
years. Since islet autoimmunity and multiple islet autoanti-
bodies are known to confer over 70% risk to the development
of type 1 diabetes within 10 years [4], it was important to
consider these markers as surrogate endpoints when analysing
a hypothetical increased risk of the disease during the first few
years after the vaccination. By examining for risk of
seroconversion to two or more islet autoantibodies as an
endpoint along with type 1 diabetes, we have enabled an
earlier detection of an increased or decreased risk of clinical
type 1 diabetes.
Among a wide range of data currently being collected in
TEDDY, vaccination records are prospectively documented in
the study. Pandemrix® was used exclusively as the H1N1
vaccine in Sweden and Finland. Other types of vaccine were
Table 2 Association between
H1N1 vaccination and type 1 di-
abetes outcomes before age
10 years adjusting for sex, family
history of type 1 diabetes,
probiotics before 90 days, mater-
nal education, maternal age,HLA-
DR-DQ high-risk genotypes, INS-
23Hph1 (rs689), PTPN22
R620W (rs2476601), CTLA4
T17A (rs231775), SNPs
rs2292239 in ERBB3, rs3184504
in SH2B3, rs10517086 and
rs12708716 in CLEC16A, and
rs4948088 in COBL
Variable Multiple proportional hazard model of H1N1 on type 1 diabetes outcomes
First appearing islet autoantibodies Multiple islet
autoantibodies
Type 1 diabetes
IAA GADA Any
HR p value HR p value HR p value HR p value HR p value
Adjusteda 0.64 0.10 0.78 0.29 0.75 0.07 0.85 0.41 0.67 0.09
Finland
Adjusteda 0.38 0.01 0.55 0.12 0.47 0.002 0.50 0.02 0.38 0.003
< 2 yearsb 0.30 0.009 1.18 0.79 0.51 0.03 0.45 0.04 0.25 0.002
≥ 2 yearsb 0.52 0.35 0.51 0.14 0.51 0.06 0.58 0.21 0.62 0.34
Sweden
Adjusteda 0.88 0.70 0.98 0.96 1.03 0.89 1.33 0.34 1.19 0.67
< 2 yearsb 0.79 0.57 1.08 0.87 0.96 0.88 1.31 0.46 1.81 0.33
≥ 2 yearsb 0.32 0.15 1.12 0.81 0.97 0.94 1.33 0.57 0.82 0.70
a Variable included in multivariate proportional hazards model; all variables available on 2966 children at risk of
islet autoantibodies, of which 214 developed islet autoantibodies; 3037 observed at risk for multiple islet auto-
antibodies, of which 140 developed multiple islet autoantibodies; and 3103 observed at risk for type 1 diabetes, of
which 91 developed type 1 diabetes
b Age of child on 1 March 2010
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used in the USA as part of the H1N1 vaccination programme.
In Germany, Pandemrix® was used as part of the vaccination
programme, but it had low coverage. Due to heterogeneity and
low numbers, we did not include the German TEDDY
population in this analysis. Therefore, these analyses were
limited to Swedish and Finnish children. A weakness in our
study is that our population was selected for HLA genotypes
associated with risk for type 1 diabetes [12]. One cannot
exclude the possibility that the vaccine may increase the risk
of islet autoimmunity in children with lower risk genotypes,
who were screened but not enrolled for follow-up in TEDDY.
This may be further emphasised by the observation that all
children who developed narcolepsy after the Pandemrix®
vaccination had HLA genotypes containing HLA-
DQB1*06:02 [10]. Because the DQ-0602 genotype is
actually protective against the development of type 1
diabetes, children with this genotype were excluded from the
TEDDY study. As HLA plays such a critical role in the
presentation of antigens to the immune system and how the
immune system reacts immunologically to infections,
individuals with different HLA genotypes are known to react
differentially to vaccinations [20].
After the reports of the increased incidence of
narcolepsy, studies were established to examine for a
possible influence of the Pandemrix® vaccination on the
incidence of other autoimmune diseases. In one of these
studies investigating the incidence of type 1 diabetes,
along with other immunological diseases, the authors
found a non-significant increased incidence of type 1
diabetes [21]. This finding was further discussed in a
number of letters to the journal, indicating that missing
data and the exclusion of various participants would have
resulted in the lack of significance [22–24]. In our
current study, we do not find any indication of increased
incidence of islet autoimmunity or type 1 diabetes after
vaccination with Pandemrix®. It is also important to
emphasise that our prospective cohort study did not suffer
from the same kind of missing data issues that affected the
results of the previous study. Similar to our study, in 355
Swedish children who were diagnosed with type 1 diabetes
during the vaccination campaign, younger individuals
(< 3 years) with HLA DQ2/2 or 2/X were low responders
to Pandemrix®, measured as antibodies against A/H1N1
haemagglutinin [25]. As the proportion of children < 3 years
of age with the high-risk HLA DQ2/8 decreased after the
vaccination, it was suggested that the vaccine affected
clinical onset of type 1 diabetes by delaying onset in
children with this genotype [25]. However, these studies
were performed shortly after the vaccination and included
only clinical type 1 diabetes and not islet autoimmunity as
an endpoint. Therefore, an increase in type 1 diabetes
could have been missed, since it would not be obvious
until long after an increase in islet autoimmunity. Our
current study is the first to investigate islet autoimmunity
and multiple islet autoantibodies in relation to the
vaccination. Another possibility would be to investigate
if Pandemrix® affected progression from islet autoanti-
bodies to clinical type 1 diabetes. Since autoantibodies
appear early, while progression to type 1 diabetes may take
many years, more time is needed to investigate progression
to type 1 diabetes properly in our prospective study as the
peak incidence has not yet been reached. The TEDDY
children will be followed to age 15 years, and additional
analyses will be done later on in the study.
Interestingly, when separating Swedish and Finnish
data, we found that Finnish children had a decreased risk of
islet autoimmunity (primarily IAA as first autoantibody),
multiple islet autoantibodies and type 1 diabetes after
vaccination. Incidence of type 1 diabetes outcomes is known
to be higher in Finland compared with Sweden [26]; however,
it is unclear as to why there was no increased risk among the
vaccinated population. We noted that the majority (58.7%) of
the H1N1-vaccinated Finnish children and only 27.6% of
those not H1N1-vaccinated had received a prior seasonal flu
vaccination, while only 1.2% of Swedish children had
received previous seasonal flu vaccination with no difference
between H1N1 vaccination rates. One could speculate that the
immunological memory induced by previous flu
vaccinations, regardless of the adjuvant in those vaccines, in
Finnish children led to improved immune responses to H1N1
virus (a priming effect). After adjusting for seasonal flu
v ac c i n a t i on , du r i ng and a f t e r p r e gnancy, t h e
associations with type 1 diabetes outcomes in Finland
remained.
Nevertheless, it is possible that influenza virus
infections may increase the risk of type 1 diabetes, as
reported by previous studies [27, 28], while others could
not confirm this [29]. It is interesting to note that repeated
doses of Pandemrix® were more frequent in Sweden than
in Finland. One could speculate that these booster
vaccinations may have led to better protection against
H1N1 infections in Sweden. This, in turn, could have
reduced the circulation of the virus and also partially
protected non-vaccinated children in Sweden. While
preliminary, these findings generate additional questions
that will be further examined in TEDDY, in which analyses
of virome data will be performed in the near future, and
warrants study in larger cohorts to evaluate possible
protective associations between influenza infections and
vaccinations and islet autoimmunity.
In conclusion, our analyses did not find any increased risk
of islet autoimmunity, multiple islet autoantibodies or type 1
diabetes in children who were given the ASO3-containing
Pandemrix® flu vaccination during the H1N1 pandemic in
2009–2010. Additional studies are needed to further explore
the potential protective effects of influenza vaccinations.
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